Cargando…
Clinical benefit of long-term use of dual antiplatelet therapy for acute myocardial infarction patients with the PEGASUS-TIMI 54 criteria
BACKGROUND: We evaluated the effectiveness of extended dual antiplatelet therapy (DAPT) usage after 2nd-generation drug elution stent implantation in acute myocardial infarction (AMI) survivors with high ischemic risk characteristics who had no major bleeding for 24 months under at least 1 year of D...
Autores principales: | Lee, Kwan Yong, Hwang, Byung-Hee, Choo, Eun-Ho, Lim, Sungmin, Kim, Chan Jun, Kim, Jin-Jin, Byeon, Jaeho, Choi, Ik Jun, Oh, Gyu Chul, Choi, Yoon Seok, Yoo, Ki Dong, Chung, Wook Sung, Ahn, Youngkeun, Jeong, Myung Ho, Chang, Kiyuk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712205/ https://www.ncbi.nlm.nih.gov/pubmed/36465433 http://dx.doi.org/10.3389/fcvm.2022.1017533 |
Ejemplares similares
-
Implications of the PEGASUS-TIMI 54 trial for US clinical practice
por: Bradley, Steven M, et al.
Publicado: (2017) -
Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54
por: Bonaca, Marc P., et al.
Publicado: (2018) -
Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial
por: Bergmark, Brian A., et al.
Publicado: (2021) -
Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS‐TIMI 54 Trial
por: Furtado, Remo H. M., et al.
Publicado: (2020) -
Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54
por: Dellborg, Mikael, et al.
Publicado: (2019)